ClinicalTrials.gg
Status unknownNCT04540185OPV-NA831Updated Sep 9, 2020

A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19

A Phase 3 interventional study of Biological: oral polio vaccine and Comparable Placebo in Covid19, SARS (Severe Acute Respiratory Syndrome) and SARS-CoV Infection, sponsored by Biomed Industries, Inc.. Status unknown at 10 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-09.

Sponsored by Biomed Industries, Inc. · Phase 3, Interventional, and Prevention

How we know

The sponsor has not verified this record recently (last verified Sep 2020), so the status shown — last known as Enrolling by invitation — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,860 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Planned enrollment
80th of 1,322
3,600 · median 92
Started
2020
with 817 others
Phase 3
174 of 1,860
10 open now
Registered
660th of 1,860
by date

Among the 1,860 studies in COVID-19 with a site in United States, this one is the 80th largest by planned enrollment of the 1,322 interventional ones that give a count, is one of 818 that started in 2020, is one of 174 in phase 3, and was the 660th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,860 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,860 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

In this randomized double blind Phase 3 clinical trial we will study the efficacy and safety of oral polio vaccine with and without NA-831 versus placebo.

Read the detailed description

Early clinical studies showed that besides protecting against poliomyelitis, oral polio vaccine (OPV) reduced the number of other viruses that could be isolated from immunized children, compared with placebo recipients.

Both poliovirus and coronavirus are positive-strand RNA viruses; therefore, it is likely that they may induce and be affected by common innate immunity mechanisms. Recent reports indicate that COVID-19 may result in suppressed innate immune responses. Stimulation by live attenuated oral polio vaccines could increase resistance to infection by the causal virus, severe acute respiratory syndrome-SARS-CoV-2.

It has been discovered that SARS-CoV-2 viruses (Covid-19) can directly invade the nervous system of patients, instead of injuring the nervous system through the immune response. Increasing evidence suggests that infection with SARS-CoV-2 causes neurological deficits in a substantial proportion of affected patients. It was observed that patients surviving COVID-19 are at high risk for subsequent development of neurological disease and in particular Alzheimer's disease.

NA-831 is a new neuroprotective and neurogenesis drug that has been demonstrated its promising safety and efficacy in Phase 2A for the treatment of early onset ofAlzheimer's disease. NA-831 in oral formulation is well tolerated NA-831 with no adverse effects.

The Phase 3 clinical trial will evaluate the safety and efficacy of OPV with and without NA-831 versus placebo.

03

Conditions studied

  • Covid19
  • SARS (Severe Acute Respiratory Syndrome)
  • SARS-CoV Infection
  • SARS-CoV-2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are at high risk of SARS-CoV-2 infection, defined as adults whose locations or circumstances put them at appreciable risk of exposure to SARS-CoV-2 and COVID-19.
  • Understands and agrees to comply with the study procedures and provides written .
  • Able to comply with study procedures based on the assessment of the Investigator.
  • Female participants of non- may be enrolled in the study. Non-childbearing potential is defined as surgically sterile (history of bilateral tubal ligation, bilateral oophorectomy, hysterectomy) or (defined as amenorrhea for ≥12 consecutive months prior to Screening without an alternative medical cause). A follicle-stimulating hormone (FSH) level may be measured at the discretion of the Investigator to confirm postmenopausal status.
  • Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the following criteria:

    • Has a negative pregnancy test at Screening and on the day of the first dose (Day 1).
    • Has practiced adequate or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first dose (Day 1).
    • Has agreed to continue adequate contraception through 3 months following the second dose on Day 29.
    • Is not currently breastfeeding.
  • Male participants engaging in activity that could result in pregnancy of sexual partners must agree to practice adequate contraception and refrain from sperm donation from the time of the first dose and through 3 months after the second dose.
  • Healthy adults or adults with pre-existing medical conditions who are in stable condition. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months before enrollment.

Exclusion criteria

Exclusion Criteria:

  • Is acutely ill or febrile 72 hours prior to or at Screening. Fever is defined as a body temperature ≥38.0°C/100.4°F. Participants meeting this criterion may be rescheduled within the relevant window periods. Afebrile participants with minor illnesses can be enrolled at the discretion of the Investigator.
  • Is pregnant or breastfeeding.
  • Known history of SARS-CoV-2 infection.
  • Prior administration of an coronavirus (SARS-CoV, Middle East Respiratory Syndrome [MERS]-CoV) vaccine or current/planned simultaneous participation in another interventional study to prevent or treat COVID-19.
  • Demonstrated inability to comply with the study procedures.
  • An immediate family member or household member of this study's personnel.
  • History of anaphylaxis, urticaria, or other significant adverse reaction requiring medical intervention after receipt of a vaccine.
  • Bleeding disorder considered a to intramuscular injection or phlebotomy.
  • Has received or plans to receive a vaccine within 28 days prior to the first dose (Day 1) or plans to receive a non-study vaccine within 28 days prior to or after any dose of investigational product (except for seasonal influenza vaccine).
  • Has participated in an interventional clinical study within 28 days prior to the day of enrollment.
  • or immunodeficient state, including (HIV) infection, asplenia, and recurrent severe infections.
  • Has received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for ≥20 milligram (mg)/day of prednisone equivalent). Topical tacrolimus is allowed if not used within 14 days prior to Screening.
  • Has received systemic immunoglobulins or blood products within 3 months prior to the day of Screening.
  • Has donated ≥450 milliliters (mL) of blood products within 28 days prior to Screening.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
3,600 participants (estimated)

Study arms

  • Experimental
    Standard dose bivalent oral polio vaccine

    Biological: oral polio vaccine Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump

    Biological: Biological: oral polio vaccine

  • Placebo comparator
    Comparable Placebo- 0.10 mg/kg

    Saline administered orally on a sugar lump

    Biological: Comparable Placebo

  • Experimental
    Standard dose of NA-831

    Drug: neuroprotection NA-831 30 mg of NA-831in a capsule administered orally

    Drug: NA-831

  • Placebo comparator
    Comparable Placebo- 30mg

    30 mg of placebo in a capsule administered orally

    Drug: Comparable Placebo of drug

  • Experimental
    Standard dose of bivalent OPV and NA-831

    Biological: oral polio vaccine Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump Plus 30 mg of neuroprotection drug NA-831 in a capsule administered orally

    Combination Product: Combination of oral polio vaccine and NA-831

  • Placebo comparator
    Comparable Placebo

    Placebo of a vaccine administered orally on a sugar lump Plus 30 mg of a placebo in a capsule administered orally

    Combination Product: Comparable Placebo of Oral Polio Vaccine and Placebo of drug

Interventions

  • BiologicalOral Polio VaccineStudies of Oral Polio VaccineOral Polio Vaccine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump

    Also known as: Oral Polio Vaccine (OPV)

  • BiologicalComparable Placebo

    Placebo of a vaccine 0.1 ml administered orally on a sugar lump

    Also known as: Placebo comparator

  • Drugcyclo(prolylglycyl)Studies of cyclo(prolylglycyl)cyclo(prolylglycyl) pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Drug: NA-831 30 mg of NA-831 in a capsule administered orally

    Also known as: NA-81 is a neuroprotective drug

  • DrugComparable Placebo of drug

    Placebo 30 mg in a capsule administered orally

    Also known as: Placebo comparator

  • Combination productCombination of oral polio vaccine and NA-831

    Drug pages: Oral Polio VaccineStudies of Oral Polio VaccineOral Polio Vaccine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · cyclo(prolylglycyl)Studies of cyclo(prolylglycyl)cyclo(prolylglycyl) pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Combination of biological: Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump and drug NA-831 30 mg in a capsule administered orally

    Also known as: OPV and Drug combination

  • Combination productComparable Placebo of Oral Polio Vaccine and Placebo of drug

    Combination of biological placebo 0.1 ml administered orally on a sugar lump and drug placebo 30 mg in a capsule administered orally

    Also known as: Placebo Comparator

06

What researchers measure

Primary outcomes

  1. Number of Participants with a First Occurrence of COVID-19 Starting 14 Days after Second Dose of OPV with or without NA-831

    Number of participants infected with Covid-19 after second dose

    Time frame: Time Frame: Day 29 (second dose) up to Day 365 (1 years after second dose)

  2. Number of Participants with Adverse Events (AEs) or Medically Attended AEs (MAAEs) Leading to Withdrawal

    Number of participants with adverse events

    Time frame: Time Frame: Up to Day 365 (1 years after second dose)

Secondary outcomes

  1. Number of Participants with a First Occurrence of Severe COVID-19 Starting 14 Days after Second Dose of OPV with or without NA-831

    Clinical signs indicative of severe COVID-19 as predefined for the study.

    Time frame: Time Frame: Day 29 (second dose) up to Day 365 (1 years after second dose)

  2. Number of Participants with a First Occurrence of COVID-19 Starting 14 days after Second Dose of OPV with or without NA-831 or Placebo regardless of evidence of prior SARS-CoV-2 Infection

    Clinical signs indicative of COVID-19 and SARS-CoV-2 infection as predefined for the study.

    Time frame: Time Frame: Day 29 (second dose) up to Day 759 (2 years after second dose)

07

Study locations

10 sites
  • Coronavirus Research Institute- Testing Site
    Los Angeles, California 90095, United States
  • Coronavirus Research Institute
    Orange, California 92868, United States
  • Coronavirus Research Institute-Testing Site
    Palo Alto, California 94304, United States
  • Coronavirus Research Testing Site
    San Francisco, California 94110, United States
  • Coronavirus Research Institute-Testing Site
    Sunnyvale, California 94086, United States
  • Coronavirus Research Institute
    Sunnyvale, California 94086, United States
  • Coronavirus Research Institute-Testing Site
    Naperville, Illinois 60540, United States
  • Coronavirus Research Institute-Testing Site-
    Bronx, New York 10467, United States
  • NeuroActiva-Clinical Research Unit
    Auckland, 1010, New Zealand
  • NeuroActiva Testing Facility of NeuroActiva (New Zealand) Ltd
    Auckland, New Zealand
08

References and documents

Individual participant data

Plan to share: Yes — We plan to share the Study Protocol and other information if needed

Supporting information: Study protocol

Time frame: 90 days after completion of the study

Access criteria: To be verified and determined at a later date

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2020; primary completion for Nov 2022, 24 months later.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 24 months is above that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2020
First posted
Sep 7, 2020
StartEst.
Nov 1, 2020
Primary completionEst.
Nov 1, 2022
CompletionEst.
Dec 31, 2022
Last update
Sep 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04540185
Lead sponsor
Biomed Industries, Inc.
Responsible party
Sponsor
First posted
Sep 7, 2020
Start date
Nov 1, 2020 (estimated)
Primary completion
Nov 1, 2022 (estimated)
Completion
Dec 31, 2022 (estimated)
Last update
Sep 9, 2020

Study contacts

Lloyd Tran, PhD
study director · Coronavirus Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Oral Polio Vaccine · cyclo(prolylglycyl)

Start the discussion